Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eflornithine for Chemoprevention of Gastric Carcinogenesis
NCT02794428Phase 2Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Sep 2016
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial in gastric intestinal metaplasia (IM) and atrophic gastritis (AG) comparing Eflornithine with Eflornithine Placebo (2 arms). Primary endpoint: Gastric Epithelial Cell DNA Damage at 6 months. Started Sep 2016; status: completed.
02
Drugs
eflornithine
03
Conditions
gastric intestinal metaplasia (IM)atrophic gastritis (AG)
Beyond the preview
Go deeper on NCT02794428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02794428.